BLASUBCUTANEOUSVIAL
Approved
Sep 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
66
Mechanism of Action
erythropoietin.
Pharmacologic Class:
Erythropoiesis-stimulating Agent
Indications (8)
anemia due to: Chronic Kidney Disease (CKD) in patients on dialysisanemia due to chronic kidney disease (CKD)including patients on dialysisanemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapyupon initiationthere is a minimum of two additional months of planned chemotherapyanemiaChronic Kidney Disease
Clinical Trials (5)
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Started Mar 2021
13 enrolled
Myelodysplastic Syndromes
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Started Nov 2016
271 enrolled
Anaemia
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
Started Apr 2016
0AnemiaChronic Kidney Disease
Darbepoetin Alfa MDS Companion Protocol
Started Jun 2014
9 enrolled
Myelodysplastic Syndrome (MDS)
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
Started Jun 2014
308 enrolled
AnaemiaChronic Kidney Disease (CKD)